Personal information

Other IDs

Scopus Author ID: 57208282804
SciProfiles: 2695784
Loop profile: 1896772

Countries

Italy

Activities

Collapse all

Works (27)

Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons

Hematology Reports
2023-11-26 | Journal article
DOI: 10.3390/hematolrep15040068
Contributors: Melania Rivano; Daniele Mengato; Marco Chiumente; Andrea Messori
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Budget impact analysis: comparing the costs of nusinersen and risdiplam in the treatment of type 3 spinal muscular atrophy patients

European Journal of Hospital Pharmacy
2023-10-28 | Journal article
DOI: 10.1136/ejhpharm-2023-003733
Contributors: Maria Elisabetta Uda; Melania Rivano; Lucia Aledda; Maria Antonietta Maioli; Fabio Lombardo
Source: check_circle
Crossref

Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons

2023-09-11 | Preprint
DOI: 10.20944/preprints202309.0619.v1
Contributors: Melania Rivano; Daniele Mengato; Marco Chiumente; Andrea Messori
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons

2023-07-07 | Preprint
DOI: 10.20944/preprints202307.0060.v1
Contributors: Melania Rivano; Daniele Mengato; Marco Chiumente; Andrea Messori
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Oncostability: stability of reconstituted and diluted anticancer medicines for a possible extension of use

European Journal of Hospital Pharmacy
2023-03 | Journal article
DOI: 10.1136/ejhpharm-2021-003157
Contributors: Marco Chiumente; Melania Rivano; Debora Severino; Sara Bertoli; Anna Rita Gasbarro; Rossella Santeramo; Alessandra Pasqualini; Riccardo Provasi; Daniele Mengato; Angelo Claudio Palozzo
Source: check_circle
Crossref

Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses

Cancers
2023-03-07 | Journal article
DOI: 10.3390/cancers15061633
Contributors: Andrea Messori; Vera Damuzzo; Melania Rivano; Luca Cancanelli; Lorenzo Di Spazio; Andrea Ossato; Marco Chiumente; Daniele Mengato
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Hospital Pharmacy Response to Covid-19 Pandemic in Italy: What We Learned From the First Outbreak Wave

Journal of Pharmacy Practice
2023-02 | Journal article
DOI: 10.1177/08971900211023643
Contributors: Vera Damuzzo; Riccardo Bertin; Daniele Mengato; Marco Chiumente; Melania Rivano; Angelo Claudio Palozzo
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments

Hematology Reports
2023-01-13 | Journal article
DOI: 10.3390/hematolrep15010006
Contributors: Luca Cancanelli; Melania Rivano; Lorenzo Di Spazio; Marco Chiumente; Daniele Mengato; Andrea Messori
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

COVID-19 impact on skills and professional perceptions of the hospital pharmacist during the first outbreak wave

European Journal of Hospital Pharmacy
2022-11 | Journal article
DOI: 10.1136/ejhpharm-2021-002765
Contributors: Vera Damuzzo; Riccardo Bertin; Daniele Mengato; Marco Chiumente; Melania Rivano; Angelo Claudio Palozzo
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Applicazione dell’intelligenza artificiale per un precoce confronto di efficacia tra nuovi farmaci oncologici

Recenti Progressi in Medicina
2022-11-01 | Journal article
DOI: 10.1701/3907.38896
Contributors: Vera Damuzzo; Melania Rivano; Paolo Baldo; Luca Cancanelli; Lorenzo Di Spazio; Andrea Ossato; Marco Chiumente; Andrea Messori; Daniele Mengato
Source: Self-asserted source
Melania Rivano

Survival in Patients With Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments

2022-10-03 | Preprint
DOI: 10.20944/preprints202210.0008.v1
Contributors: Luca Cancanelli; Melania Rivano; Lorenzo Di Spazio; Marco Chiumente; Daniele Mengato; Andrea Messori
Source: check_circle
Crossref

Survival with novel hormonal therapies in patients with nonmetastatic castration-resistant prostate cancer: indirect comparison of three randomized phase-III trials

World Journal of Urology
2022-09-09 | Journal article
DOI: 10.1007/s00345-022-04143-8
Contributors: Melania Rivano; Luca Cancanelli; Lorenzo Di Spazio; Daniele Mengato; Marco Chiumente; Andrea Messori
Source: check_circle
Crossref

First-Line Chemoimmunotherapy Versus Chemotherapy in PD-L1-Negative Patients with Non-Small-Cell Lung Cancer

Immunotherapy
2022-08 | Journal article
DOI: 10.2217/imt-2021-0208
Contributors: Daniele Mengato; Luca Cancanelli; Melania Rivano; Marco Chiumente; Lorenzo Di Spazio; Andrea Messori
Source: check_circle
Crossref

The “One-to-Many” Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma

Cureus
2022-08-25 | Journal article
DOI: 10.7759/cureus.28369
Part of ISSN: 2168-8184
Contributors: Andrea Messori; Melania Rivano; Luca Cancanelli; Vera Damuzzo; Andrea Ossato; Marco Chiumente; Daniele Mengato
Source: Self-asserted source
Melania Rivano

Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy

Int. Journal of Clinical Pharmacology and Therapeutics
2022-08-01 | Journal article
DOI: 10.5414/cp204243
Part of ISSN: 0946-1965
Contributors: Melania Rivano
Source: Self-asserted source
Melania Rivano

A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia

Leukemia & Lymphoma
2022-04-16 | Journal article
DOI: 10.1080/10428194.2021.2022141
Contributors: Andrea Messori; Melania Rivano; Daniele Mengato; Luca Cancanelli; Lorenzo Di Spazio; Marco Chiumente
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors

Cureus
2022-01-09 | Journal article
DOI: 10.7759/cureus.21065
Part of ISSN: 2168-8184
Source: Self-asserted source
Melania Rivano

The qosmos study: Pharmacist-led multicentered observational study on quality of life in multiple sclerosis

Neurology International
2021 | Journal article
DOI: 10.3390/neurolint13040065
EID:

2-s2.0-85121330044

Part of ISSN: 20358377 20358385
Contributors: Damuzzo, V.; Agnoletto, L.; Rampazzo, R.; Cammalleri, F.; Cancanelli, L.; Chiumente, M.; Costantino, S.; Michielan, S.; Milani, F.; Sartori, A. et al.
Source: Self-asserted source
Melania Rivano via Scopus - Elsevier

Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials

Cureus
2021-11-25 | Journal article
DOI: 10.7759/cureus.19893
Part of ISSN: 2168-8184
Source: Self-asserted source
Melania Rivano

Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy

Int. Journal of Clinical Pharmacology and Therapeutics
2021-11-15 | Journal article
DOI: 10.5414/cp204113
Part of ISSN: 0946-1965
Source: Self-asserted source
Melania Rivano
grade
Preferred source (of 2)‎

Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital

Global & Regional Health Technology Assessment
2021-03-26 | Journal article
DOI: 10.33393/grhta.2021.2202
Contributors: Marco Chiumente; Alberto Russi; Federica Todino; Daniele Mengato; Marina Coppola; Melania Rivano; Angelo Claudio Palozzo; Claudio Jommi
Source: check_circle
Crossref

Restricted Mean Survival Time as Outcome Measure in Advanced Urothelial Bladder Cancer: Analysis of 4 Clinical Studies

Immunotherapy
2021-02 | Journal article
DOI: 10.2217/imt-2020-0160
Contributors: Melania Rivano; Luca Cancanelli; Lorenzo Di Spazio; Marco Chiumente; Daniele Mengato; Andrea Messori
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Restricted mean survival time in advanced non-small cell lung cancer treated with immune checkpoint inhibitors

European Review for Medical and Pharmacological Sciences
2021-02 | Journal article
DOI: 10.26355/eurrev_202102_25083
Source: Self-asserted source
Melania Rivano
grade
Preferred source (of 2)‎

Tyrosine-kinase inhibitor discontinuation in chronic myeloid leukaemia after deep molecular response: a meta-analysis with meta-regression

Journal of Chemotherapy
2020-07-03 | Journal article
DOI: 10.1080/1120009X.2020.1716492
Contributors: Melania Rivano; Luca Cancanelli; Andrea Zovi; Chiara Addis; Daniele Mengato; Marco Chiumente; Andrea Messori
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Galenic Preparation of 40% Dextrose Gel: A New Approach to the Management of Neonatal Hypoglycemia

Clinical Medicine Insights: Endocrinology and Diabetes
2020-01 | Journal article
DOI: 10.1177/1179551420928326
Contributors: Melania Rivano; Maria Albrecht; Giorgia Longobardo; Cinzia Veneziano
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Heterogeneity of the Italian residency training in hospital pharmacy: A pilot study from students' perspective

Journal de Pharmacie Clinique
2018 | Journal article
DOI: 10.1684/jpc.2018.0403
EID:

2-s2.0-85064341107

Part of ISSN: 19524064 02911981
Contributors: Damuzzo, V.; Langella, R.; Mengato, D.; Rivano, M.; Lamesta, C.; Cancanelli, L.; Confalonieri, C.; Badiani, B.; Pigozzo, S.; Realdon, N.
Source: Self-asserted source
Melania Rivano via Scopus - Elsevier

Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model

International Journal of Pharmaceutics
2016-11 | Journal article
DOI: 10.1016/j.ijpharm.2016.06.125
Part of ISSN: 0378-5173
Source: Self-asserted source
Melania Rivano
grade
Preferred source (of 2)‎
How many people are using ORCID?